Gene Patents Under Fire: Weighing the Costs and Benefits

Christopher M. Holman, Gene Patents under Fire: Weighing the Costs and Benefits, book chapter in BIOTECHNOLOGY AND SOFTWARE PATENT LAW: A COMPARATIVE REVIEW ON NEW DEVELOPMENTS, edited by Emanuela Arezzo and Gustavo Ghidini, Edward Elgar Publishing (2011).

28 Pages Posted: 17 Nov 2010 Last revised: 18 Feb 2015

Christopher M. Holman

University of Missouri - Kansas City School of Law

Date Written: November 16, 2010

Abstract

Gene patents form the intellectual property platform for companies to translate biomedical research into life-saving therapeutic and diagnostic agents. These patents are also controversial, with critics charging that gene patents are unjustified, and they substantially impede research and access to genetic diagnostic testing. Myriad Genetics, the exclusive licensee of patents relating to the BRCA breast cancer susceptibility genes, has been a lightning rod for much of the negative commentary on gene patents. The criticism has culminated in a lawsuit by the ACLU challenging the patent eligibility of Myriad’s gene patents, and by implication the eligibility of gene patents in general. On March 29, 2010, the district court ruled in favor of the ACLU, invalidating all of the challenged patent claims for encompassing subject matter ineligible for protection under Section 101 of the patent statute. As of November 2010 the case is at the Court of Appeals for the Federal Circuit, and thus the status of gene patents is still very much in play. This chapter explains what a gene patent is, and discusses the legal doctrine supporting the USPTO’s position that gene patents are valid. It also considers the societal costs and benefits of gene patents, their role in biotechnology research and development, and the ACLU’s challenge to Myriad’s patents. It explain why many of Myriad’s patent claims challenged by the ACLU for impeding BRCA genetic testing are likely invalid for lack of novelty or obviousness, or not infringed by BRCA testing as currently performed. It explains why the human gene patent thicket has for the most part failed to materialize, particularly with respect to basic research and the use of DNA hybridization arrays. It concludes with suggestions for more appropriate and measured alternatives to the doctrine of patent eligibility for reining in truly unworthy gene patents.

Keywords: Myriad, ACLU, patents, patent law, patent eligibility, patentable subject matter, gene patents, DNA patents, biotechnology, Section 101, BRCA, genetic testing, diagnostic testing

JEL Classification: K20, K23, K32, O31, O32, O33, O34, O38

Suggested Citation

Holman, Christopher M., Gene Patents Under Fire: Weighing the Costs and Benefits (November 16, 2010). Christopher M. Holman, Gene Patents under Fire: Weighing the Costs and Benefits, book chapter in BIOTECHNOLOGY AND SOFTWARE PATENT LAW: A COMPARATIVE REVIEW ON NEW DEVELOPMENTS, edited by Emanuela Arezzo and Gustavo Ghidini, Edward Elgar Publishing (2011).. Available at SSRN: https://ssrn.com/abstract=1710150 or http://dx.doi.org/10.2139/ssrn.1710150

Christopher M. Holman (Contact Author)

University of Missouri - Kansas City School of Law ( email )

5100 Rockhill Road
Kansas City, MO 64110-2499
United States

Paper statistics

Downloads
317
Rank
77,035
Abstract Views
1,919